StockWatch: ARK Mostly Bullish on CRISPR Therapeutics
Expanding Access to Gene Therapies: Addressing Patient Burden, High Costs
Can Global Policies Boost Biosimilar Adoption Work in the US?
A Guide to Patient Financial Assistance Programs
Biosimilar Interchangeability: FDA Designation, Marketing Exclusivity, Guidance, and Future Trends
Understanding Limited Distribution Networks
Why Haven't More Patients Been Treated With the Gene Therapies for Sickle Cell Disease? | AMCP Nexus 2024
Can Outcomes-Based Agreements Work for Weight Loss Drugs?
Upcoming Biosimilars and the Impact of IRA: Key Takeaways From Jeffrey Casberg
Biosimilars in America: Overcoming Barriers and Maximizing Impact
IPD Analytics' Jeffrey Casberg Discusses Recent Biosimilar Approvals
Jeffrey Casberg of IPD Analytics Gives Insight on Specialty Drugs in the Pipeline
IPD Analytics' Jeffrey Casberg Says IRA, PBM Legislation Reshape US Drug Costs
Key Pharmaceutical Pipeline Developments: Insights from Industry Experts
Additional Price Cuts to Insulin are on the Way
Jeffrey Casberg Predicts Generic, Biosimilar Competition in the Pharmaceutical Market
AMCP 2024: Key Takeaways From Leading Speakers
Introduction to Digital Therapeutics and Potential Payer Management
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
Potential Generics Could Lower Prices for Oncology, Cardiovascular Drugs | AMCP 2024
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
Why Every Hospital Needs a Chief Pharmacy Officer in the C-Suite
2024 Prediction from Jeffrey Casberg, M.S., RPh
Biosimilars are Ascendant